Impact of conjugate pneumococcal vaccines on the changing epidemiology of pneumococcal infections

References

• Adam D. Issues in pneumococcal disease and pneumococcal conjugate vaccines: highlights of the 27th meeting of ESPID. Brussels, Belgium June, 9–13, 2009. Vaccine27(50), 7133–7137 (2009).
   PubMedGoogle Scholar
• Rose M, Zielen S. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe. Expert Rev. Vaccines8(10), 1351–1364 (2009).
   PubMed Web of Science ®Google Scholar
• CDC. Progress in introduction of pneumococcal cojugate vaccine worldwide. MMRW Morb. Mortal. Wkly Rep.57(42), 1148–1151 (2008).
   PubMedGoogle Scholar
• Dinleyici EC, Yargic ZA. Pneumococcal conjugated vaccine: PHiD-CV. Expert Rev. Anti Infect. Ther.7(9), 1063–1074 (2009).
   PubMed Web of Science ®Google Scholar
• Musher D. Streptococcus pneumoniae. In: Principles and Practice of Infectious Diseases (Volume 7). Mandell GL (Ed.). Churchill Livingstone Elsevier Publishers, PA, USA, 2623–2642 (2010).
   Google Scholar
• Hirschmann J, Lipsky B. Pneumococcal vaccine in the United States: a critical analysis. JAMA246(13), 1428–1432 (1981).
   PubMedGoogle Scholar
• World Health Organization. Pneumococcal conjugate vaccine for childhood immunization. Wkly Epidemiol. Rec.82, 93–104 (2007).
   PubMedGoogle Scholar
• Black S, Shinefield H, Fireman B et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr. Infect. Dis. J.19(3), 187–195 (2000).
   PubMed Web of Science ®Google Scholar
• Eskola J, Kilpi T, Palmu A et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N. Engl. J. Med.344(6), 403–409 (2001).
   PubMed Web of Science ®Google Scholar
• Oosterhuis-Kafeja F, Beutels P, Van Damme P. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998–2006). Vaccine25(12), 2194–2212 (2007).
   PubMed Web of Science ®Google Scholar
• Dinleyici EC, Yargic ZA. Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era. Expert Rev. Vaccines7(9), 1367–1394 (2008)
   PubMed Web of Science ®Google Scholar
• CDC. Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children: Advisory Committee on Immunization Practices (ACIP). MMWR Morb. Mortal. Wkly Rep.59(9), 258–261 (2010).
   PubMedGoogle Scholar
• Dinleyici E, Zeynel A. Current knowledge regarding the investigational 13-valent pneumococcal vaccine. Expert Rev. Vaccines977–986 (2009).
   PubMedGoogle Scholar
• Liu Y, Wang H, Chen M et al. Serotype distribution and antimicrobial resistance patterns of Streptococcus pneumoniae isolated from children in China younger than 5 years. Diagn. Microbiol. Infect. Dis.61(3), 256–263 (2008).
   PubMed Web of Science ®Google Scholar
• Muñoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin. Infect. Dis.46(2), 174–182 (2008).
   PubMed Web of Science ®Google Scholar
• O’Dempsey TJ, McArdle TF, Lloyd-Evans N et al. Pneumococcal disease among children in a rural area of West Africa. Pediatr. Infect. Dis. J. (5), 431–437 (1996).
   PubMedGoogle Scholar
• Byington CL, Hulten KG, Ampofo K et al. Molecular epidemiology of pediatric pneumococcal empyema from 2001 to 2007 in Utah. J. Clin. Microbiol.48(2), 520–525 (2010).
   PubMed Web of Science ®Google Scholar
• CDC. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine – United States, 2007. MMWR Morb. Mortal. Wkly Rep.59(9), 253–257 (2010).
   PubMedGoogle Scholar
• De Wals P, Black S, Borrow R, Pearce D. Modeling the impact of a new vaccine on pneumococcal and nontypable Haemophilus influenzae diseases: a new simulation model. Clin. Ther.31(10), 2152–2169 (2009).
   PubMed Web of Science ®Google Scholar
• Croxtall JD, Keating GM. Pneumococcal polysaccharide protein D-conjugate vaccine (Synflorix; PHiD-CV). Paediatr. Drugs11(5), 349–357 (2009).
   PubMedGoogle Scholar
• Knufa M, Habermehl P, Cimino C, Petersen G, Schmitt H. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa–HBV–IPV/Hib combination vaccine in healthy infants. Vaccine24, 4727–4736 (2006).
   PubMedGoogle Scholar
• CDC. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 24–59 months who are not completely vaccinated. MMWR Morb. Mortal. Wkly Rep.57(13), 343–344 (2008).
   PubMedGoogle Scholar
• Whitney CG, Pilishvili T, Farley MM et al. Effectiveness of 7-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case–control study. Lancet368(9546), 1495–1502 (2006).
   PubMed Web of Science ®Google Scholar
• Schuchat A, Bell BP. Monitoring the impact of vaccines postlicensure: new challenges, new opportunities. Expert Rev. Vaccines7(4), 437–456 (2008).
   PubMed Web of Science ®Google Scholar
• D’angio C, Heyne R, O’Shea T et al. Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants. Pediatr. Infect. Dis. J.29(7), 600–606 (2010).
   PubMed Web of Science ®Google Scholar
• Madhi S, Adrian P, Kuwanda L et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. Vaccine25(13), 2451–2457 (2007).
   PubMed Web of Science ®Google Scholar
• French N, Gordon S, Mwalukomo T et al. A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N. Engl. J. Med.362(9), 812–822 (2010).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Recommendations for the production and control of pneumococcal conjugate vaccines. Technical Report Series. No. 927. WHO, Geneva, Switzerland (2005).
   Google Scholar
• Feavers I, Knezevic I, Powell M, Griffiths E. Challenges in the evaluation and licensing of new pneumococcal vaccines, 7–8 July 2008, Ottawa, Canada. Vaccine27(28), 3681–3688 (2009).
   PubMed Web of Science ®Google Scholar
• Käyhty H, Ahman H, Eriksson K, Sörberg M, Nilsson L. Immunogenicity and tolerability of a heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 12 months of age. Pediatr. Infect. Dis. J.24(2), 108–114 (2005).
   PubMed Web of Science ®Google Scholar
• Givon-Lavi N, Greenberg D, Dagan R. Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine: a randomized controlled trial. Pediatr. Infect. Dis. J.29(8), 756–762 (2010).
   PubMed Web of Science ®Google Scholar
• Pelton S, Weycker D, Klein J, Strutton D, Ciuryla V, Oster G. 7-valent pneumococcal conjugate vaccine and lower respiratory tract infections: effectiveness of a 2-dose versus 3-dose primary series. Vaccine28(6), 1575–1582 (2010).
   PubMed Web of Science ®Google Scholar
• Vesikari T, Wysocki J, Chevallier B et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine Pediatr. Infect. Dis. J.28(4), S66–S76 (2009).
   PubMed Web of Science ®Google Scholar
• Dagan R, Frasch C. Clinical characteristics of a novel 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine candidate (PHiD-CV). Introduction. Pediatr. Infect. Dis. J.28(Suppl. 4), S63–S65 (2009).
   PubMedGoogle Scholar
• Esposito S, Tansey S, Thompson A et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlers. Clin. Vaccine Immunol.17(6), 1017–1026 (2010).
   PubMed Web of Science ®Google Scholar
• Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg. Infect. Dis.5(3), 336–345 (1999).
   PubMed Web of Science ®Google Scholar
• Aaberge I. Experience with pneumoccocal conjugate vaccine in Norway. Expert Rev. Vaccines8(2), 159–165 (2009).
   PubMed Web of Science ®Google Scholar
• Pilishvili T, Lexau C, Farley MM et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J. Infect. Dis.201(1), 32–41 (2010).
   PubMed Web of Science ®Google Scholar
• Pelton SI, Huot H, Finkelstein JA et al. Emergence of 19A as virulent and multidrug resistant pneumococcus in massachusetts following universal immunization of infants with pneumococcal conjugate vaccine Pediatr. Infect. Dis. J.26(6), 468–472 (2007).
   PubMed Web of Science ®Google Scholar
• Kaplan SL, Mason EO Jr, Wald ER et al. Decrease of invasive pneumococcal infections in children among 8 children’s hospitals in the United States after the introduction of the 7-valent pneumococcal conjugate vaccine. Pediatrics125(3), 443–449 (2010).
   Google Scholar
• Farrell D, Klugman K, Pichichero M. Increased antimicrobial resistance among nonvaccine serotypes of Streptococcus pneumoniae in the pediatric population after the introduction of 7-valent pneumococcal vaccine in the United States. Pediatr. Infect. Dis. J.26(2), 123–128 (2007).
   PubMed Web of Science ®Google Scholar
• Isaacman D, McIntosh E, Reinert R. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int. J. Infect. Dis.14(3), 197–209 (2010).
   PubMed Web of Science ®Google Scholar
• Mera R, Miller L, Fritsche T, Jone R. Serotype replacement and multiple resistance in Streptococcus pneumoniae after the introduction of the conjugate pneumococcal vaccine. Microb. Drug Resist.14(2), 101–107 (2008).
   PubMed Web of Science ®Google Scholar
• Long S. Capsules, clones, and curious events: pneumococcus under fire from polysaccharide conjugate vaccine Clin. Microbiol. Infect.41, 30–34 (2005).
   Google Scholar
• Choi E, Kim S, Eun B, Kim S, Kim N, Lee J. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg. Infect. Dis.14(2), 271–281 (2008).
   Google Scholar
• Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, Porat N. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J. Infect. Dis.199, 776–785 (2009).
   PubMed Web of Science ®Google Scholar
• Mera R, Miller L, Amrine-Madsen H, Sahm D. The impact of the pneumococcal conjugate vaccine on antimicrobial resistance in the United States since 1996: evidence for a significant rebound by 2007 in many classes of antibiotics. Microb. Drug Resist.15(4), 261–268 (2008).
   Google Scholar
• Gertz RE, Li Z, Pimenta FC et al. Increased penicillin nonsusceptibility of nonvaccine-serotype invasive pneumococci other than serotypes 19A and 6A in post-7-valent conjugate vaccine era. J. Infect. Dis.201(5), 770–775 (2010).
   PubMed Web of Science ®Google Scholar
• Whitney C, Farley M, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein–polysaccharide conjugate vaccine N. Engl. J. Med.348(18), 1737–1746 (2003).
   PubMed Web of Science ®Google Scholar
• Rodgers G, Arguedas A, Cohen R. Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines. Vaccine27(35), 4739–4740 (2009).
   PubMedGoogle Scholar
• Rodgers G, Arguedasb A, Cohenc R, Dagan R. Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines. Vaccine27(29), 3802–3810 (2009).
   PubMed Web of Science ®Google Scholar
• Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA298(15), 1772–1778 (2007).
   PubMed Web of Science ®Google Scholar
• Grijalba CG, Poehling KA, Nuorti JP et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics118(3), 865–873 (2006).
   PubMedGoogle Scholar
• Zhou F, Shefer A, Kong Y, Nuorti P. Trends in acute otitis media-related healthcare utilization by privately insured young children in the United States, 1997–2004. Pediatrics121(2), 253–260 (2008).
   PubMed Web of Science ®Google Scholar
• De Wals P, Carbon M, Sevin E, Deceuninck G, Ouakki M. Reduced physician claims for otitis media after implementation of pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr. Infect. Dis. J.28(9), e271–e275 (2009).
   PubMedGoogle Scholar
• Brook I, Gober A. Frequency of recovery of pathogens from the nasopharynx of children with acute maxillary sinusitis before and after the introduction of vaccination with the 7-valent pneumococcal vaccine. Int. J. Pediatr. Otorhinolaryngol.71(4), 575–579 (2007).
   PubMed Web of Science ®Google Scholar
• Mc Neil JC, Hulten, KG, Mason EO, Kaplan SL. Serotype 19A is the most common Streptococcus pneumoniae isolate in children with chronic sinusitis. Pediatr. Infect. Dis. J.28(9), 766–768 (2009).
   PubMedGoogle Scholar
• Grijalva C, Nuort J, Arbogast P. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet369, 1179–1186 (2007).
   PubMed Web of Science ®Google Scholar
• Koshy E, Murray J, Bottle A, Sharland M, Saxena S. Impact of the 7-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997–2008. Thorax65, 770–774 (2010).
   PubMed Web of Science ®Google Scholar
• Rubin J, McGarry L, Klugman K, Strutton D, Gilmore K, Weinstein M. Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic. BMC Infect. Dis.10(14), 3–11 (2010).
   PubMedGoogle Scholar
• Klugman K, Chien Y, Madhi S. Pneumococcal pneumonia and influenza: a deadly combination. Vaccine27(Suppl. 3), C9–C14 (2009).
   PubMed Web of Science ®Google Scholar
• Liñares J, Ardanuy C, Pallares R, Fenoll A. Changes in antimicrobial resistance, serotypes, and genotypes in Streptococcus pneumoniae over a thirty-year period. Clin. Microbiol. Infect.16(5), 402–410 (2010).
   PubMed Web of Science ®Google Scholar
• Karnezis T, Smith A, Whittier S, Haddad J, Saiman L. Antimicrobial resistance among isolates causing invasive pneumococcal disease before and after licensure of heptavalent conjugate pneumococcal vaccine. PLoS ONE4(6), e5965 (2009).
   PubMedGoogle Scholar
• Kyaw M. Effect of Introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N. Engl. J. Med.354(14), 1455–1466 (2006).
   PubMed Web of Science ®Google Scholar
• Dagan R, Klugman K. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect. Dis.8(12), 785–795 (2008).
   PubMed Web of Science ®Google Scholar
• Harboe Z, Benfield T, Valentiner-Branth P et al. Temporal trends in invasive pneumococcal disease and pneumococcal serotypes over 7 decades. Clin. Infect. Dis.50(3), 329–337 (2010).
   PubMed Web of Science ®Google Scholar
• Jackson L, Janoff E. Pneumococcal vaccination of elderly adults: new paradigms for protection. Clin. Infect. Dis.47(10), 1328–1338 (2008).
   PubMed Web of Science ®Google Scholar
• Obaro S. 7-valent pneumococcal conjugate vaccine for developing countries. Expert Rev. Vaccines8(8), 1051–1061 (2009).
   PubMed Web of Science ®Google Scholar
• Hak E, Grobbee D, Sanders E et al. Rationale and design of CAPITA: a RCT of 13-valent conjugated pneumococcal vaccine efficacy among older adults. Neth. J. Med.66(9), 378–383 (2008).
   PubMed Web of Science ®Google Scholar
• Wong A, Marrie T, Garg S, Kellner J, Tyrrell G. Increased risk of invasive pneumococcal disease in haematological and solid-organ malignancies. Epidemiol. Infect.138(12), 1804–1810 (2010).
   PubMed Web of Science ®Google Scholar
• Kieninger DM, Kueper K, Steul K et al. Safety and immunologic non-inferiority of 13-valent pneumococcal conjugate vaccine compared to 7-valent pneumococcal conjugate vaccine given as a 4-dose series with routine vaccines in healthy infants and toddlers. Presented at: 48th Annual ICAAC/IDSA 46th Annual Meeting. DC, USA, 25–28 October 2008.
   Google Scholar
• Kieninger DM, Kueper K, Steul K et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine28(25), 4192–4203 (2010).
   PubMed Web of Science ®Google Scholar